Updates of Healthcare Implementation Communique (SUT) published in Turkey in May 2020

Jul 2020

On 9 May 2020, the Reimbursement Commission made changes to the SUT regarding response to the COVID-19 pandemic and introduced codes for IVD tests for Covid-19 (SARS-CoV-2) reverse transcriptase PCR and detection of Covid-19 antigen, IgG, IgM.

Healthcare Implementation Communique (Sağlık Uygulama Tebliği, SUT) is legislation created in 2007 by the Social Security Institute detailing the rules of fees and prices for medical products and services.

Reimbursement fees for procedures and devices were established in 2007 (Healthcare Implementation Communique, SUT) with significant updates in 2013 and only minor adjustments several times a year since then. Minor updates related mainly to pharmaceuticals.

On 9 May 2020, the Reimbursement Commission made changes to the SUT regarding response to the COVID-19 pandemic.

The following codes for IVD tests were introduced:

907221 "Covid-19 Antigen (SARS-CoV-2) (DFA)" with the tariff of 26.96 TRY
907222 "Covid-19 (SARS-CoV-2) IgG " with the tariff of 14.10 TRY
907223 "Covid-19 (SARS-CoV-2) IgM with the tariff of 14.10 TRY
908115 "Covid-19 (SARS-CoV-2) reverse transcriptase PCR" with the tariff of 166.95 TRY
908116 "Covid-19 (SARS-CoV-2) insulation" with the tariff of 20.97 TRY

These codes can be used for reimbursement purposes only during the COVID-19 pandemic.

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

MTP Council updated recommendations on gene expression analysis for decision-making on the adjuvant breast cancer treatment

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

2022 RIHN and Supplementary list for IVD tests published in France

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Draft Order amending the Common Package of Benefits of the Spanish National Health System

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

New procedure and diagnostic codes added to the private reimbursement schedule in England

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Theme survey on products for monitoring and diagnostics of sepsis launched by Swedish TLV

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.